Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» erdafitinib
erdafitinib
Johnson & Johnson wins full FDA approval for bladder cancer therapy Balversa
Seeking Alpha
Sun, 01/21/24 - 05:11 pm
JNJ
bladder cancer
Balversa
erdafitinib
urothelial cancer
J&J Files NDA for Erdafitinib in Urothelial Cancer Indication
Yahoo/Zacks.com
Wed, 09/19/18 - 11:52 am
JNJ
erdafitinib
urothelial cancer
J&J execs say new launches and label expansions will fuel 'above-market' growth through 2021
Fierce Pharma
Fri, 09/14/18 - 09:52 am
JNJ
label expansions
esketamine
erdafitinib
J&J’s blockbuster hopeful erdafitinib gets ‘breakthrough’ moniker
Endpoints
Thu, 03/15/18 - 09:56 am
JNJ
erdafitinib
breakthrough therapies
metastatic urothelial cancer